FDA Brief

Warning letters Drugs

FDA warning letter to

Integrity Partners Group

High riskIssued Dec 15, 2025Posted Jan 20Center for Drug Evaluation and Research (CDER)

FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

What happened

FDA inspected the Chemisphere Corporation drug manufacturing facility in Saint Louis, MO, from June 16 to 24, 2025. FDA found OTC drug batches released without adequate strength or microbiological testing; incoming components not tested for identity and supplier certificates not validated; drugs made on equipment shared with non-pharmaceutical products without adequate cleaning validation; and missing process and system validation, including microbial counts above action limits.

What FDA found

  1. FDA said the firm released OTC drug batches without adequate tests for active ingredient strength or microbial contamination.

    21 CFR 211.165(a) and 211.165(b)
  2. FDA said the firm did not test each incoming raw material lot for identity and relied on supplier certificates of analysis without establishing their reliability, including for high-risk components.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. FDA said the firm did not adequately validate cleaning of non-dedicated equipment also used for non-pharmaceutical products, risking cross-contamination.

    21 CFR 211.67(b)
  4. FDA said the firm lacked adequate process validation and had not qualified a manufacturing system used as a component and for cleaning; microbial results exceeded the action limit without identification or sanitization.

    21 CFR 211.100(a)
  5. FDA said the firm’s overall quality oversight is inadequate.

What FDA wants

FDA asks the company to respond in writing within 15 working days with correction plans, risk assessments, and comprehensive assessments of its laboratory, supplier, cleaning, and validation systems. It also asks for specified component test results within 30 calendar days and recommends a qualified consultant for current good manufacturing practice (CGMP).

Who should pay attention

  • brands that contract with Chemisphere or Integrity Partners Group for drug manufacturing
  • companies relying on supplier certificates of analysis for incoming drug components
  • quality teams overseeing OTC drug suppliers and shared-equipment contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk